206 related articles for article (PubMed ID: 28326252)
1. Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
Amin A; White RL
J Kidney Cancer VHL; 2014; 1(7):74-83. PubMed ID: 28326252
[TBL] [Abstract][Full Text] [Related]
2. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
Bakouny Z; El Zarif T; Dudani S; Connor Wells J; Gan CL; Donskov F; Shapiro J; Davis ID; Parnis F; Ravi P; Steinharter JA; Agarwal N; Alva A; Wood L; Kapoor A; Ruiz Morales JM; Kollmannsberger C; Beuselinck B; Xie W; Heng DYC; Choueiri TK
Eur Urol; 2023 Feb; 83(2):145-151. PubMed ID: 36272943
[TBL] [Abstract][Full Text] [Related]
3. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous regression of multiple pulmonary metastases accompanied by normalization of serum immune markers following cytoreductive nephrectomy in a patient with clear-cell renal cell carcinoma.
Okazaki A; Kijima T; Schiller P; Ishikawa N; Fuchizawa H; Takei K; Suzuki I; Sakamoto K; Tsuzuki T; Kamai T
IJU Case Rep; 2021 Mar; 4(2):95-99. PubMed ID: 33718815
[TBL] [Abstract][Full Text] [Related]
6. Bladder metastasis with additional metastases in multiple other organs 4 years after radical nephrectomy for clear cell renal cell carcinoma: a case report and review of the literature.
Urushibara M; Nagata M; Okumura T; Kano H; Matsumoto Y; Tatsuoka S; Nenohi T; Shirakawa T; Kato D; Kawamoto M; Ishizaka K; Matsutani N
J Med Case Rep; 2022 Apr; 16(1):131. PubMed ID: 35366927
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation.
Kambe T; Yamasaki T; Mine Y; Hagimoto H; Kokubun H; Kubota M; Tsutsumi N; Inoue K; Hara S; Kawakita M
IJU Case Rep; 2022 May; 5(3):168-171. PubMed ID: 35509785
[TBL] [Abstract][Full Text] [Related]
9. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
Ghoreifi A; Vaishampayan U; Yin M; Psutka SP; Djaladat H
JAMA Oncol; 2024 Feb; 10(2):240-248. PubMed ID: 38095885
[TBL] [Abstract][Full Text] [Related]
11. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for renal cell cancer in the era of targeted therapy.
Coppin C
Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800
[TBL] [Abstract][Full Text] [Related]
14. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
15. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database.
Lai GS; Li JR; Wang SS; Chen CS; Yang CK; Lin CY; Hung SC; Chiu KY; Yang SF
PLoS One; 2024; 19(3):e0299102. PubMed ID: 38547226
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of renal cell carcinoma.
deKernion JB
Prog Clin Biol Res; 1984; 153():409-21. PubMed ID: 6206509
[TBL] [Abstract][Full Text] [Related]
17. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
[TBL] [Abstract][Full Text] [Related]
18. Surgical management in metastatic renal cell carcinoma.
Pignot G
Bull Cancer; 2022 May; 109(2S):2S59-2S65. PubMed ID: 35760472
[TBL] [Abstract][Full Text] [Related]
19. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
Figlin RA; Pierce WC; Kaboo R; Tso CL; Moldawer N; Gitlitz B; deKernion J; Belldegrun A
J Urol; 1997 Sep; 158(3 Pt 1):740-5. PubMed ID: 9258071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
